Top

Published in:

01-06-2014 | Original Paper

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

Authors: Markus Mandler, Elvira Valera, Edward Rockenstein, Harald Weninger, Christina Patrick, Anthony Adame, Radmila Santic, Stefanie Meindl, Benjamin Vigl, Oskar Smrzka, Achim Schneeberger, Frank Mattner, Eliezer Masliah

Published in: Acta Neuropathologica | Issue 6/2014

Abstract

Immunotherapeutic approaches are currently in the spotlight for their potential as disease-modifying treatments for neurodegenerative disorders. The discovery that α-synuclein (α-syn) can transmit from cell to cell in a prion-like fashion suggests that immunization might be a viable option for the treatment of synucleinopathies. This possibility has been bolstered by the development of next-generation active vaccination technology with short peptides-AFFITOPEs^® (AFF)- that do not elicit an α-syn-specific T cell response. This approach allows for the production of long term, sustained, more specific, non-cross reacting antibodies suitable for the treatment of synucleinopathies, such as Parkinson’s disease (PD). In this context, we screened a large library of peptides that mimic the C-terminus region of α-syn and discovered a novel set of AFF that identified α-syn oligomers. Next, the peptide that elicited the most specific response against α-syn (AFF 1) was selected for immunizing two different transgenic (tg) mouse models of PD and Dementia with Lewy bodies, the PDGF- and the mThy1-α-syn tg mice. Vaccination with AFF 1 resulted in high antibody titers in CSF and plasma, which crossed into the CNS and recognized α-syn aggregates. Active vaccination with AFF 1 resulted in decreased accumulation of α-syn oligomers in axons and synapses, accompanied by reduced degeneration of TH fibers in the caudo-putamen nucleus and by improvements in motor and memory deficits in both in vivo models. Clearance of α-syn involved activation of microglia and increased anti-inflammatory cytokine expression, further supporting the efficacy of this novel active vaccination approach for synucleinopathies.

Available only for authorised users

Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129(2):154–169. doi:10.1111/j.1365-2567.2009.03225.x PubMedCentralPubMedCrossRef

Amschl D, Neddens J, Havas D, Flunkert S, Rabl R, Romer H, Rockenstein E, Masliah E, Windisch M, Hutter-Paier B (2013) Time course and progression of wild type alpha-synuclein accumulation in a transgenic mouse model. BMC Neurosci 14:6. doi:10.1186/1471-2202-14-6 PubMedCentralPubMedCrossRef

Angot E, Brundin P (2009) Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 3):S143–S147. doi:10.1016/S1353-8020(09)70802-8 PubMedCrossRef

Aquilano K, Baldelli S, Rotilio G, Ciriolo MR (2008) Role of nitric oxide synthases in Parkinson’s disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res 33(12):2416–2426. doi:10.1007/s11064-008-9697-6 PubMedCrossRef

Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27(34):9115–9129. doi:10.1523/JNEUROSCI.2361-07.2007 PubMedCrossRef

Bach P, Tschäpe JA, Kopietz F, Braun G, Baade JK, Wiederhold KH, Staufenbiel M, Prinz M, Deller T, Kalinke U, Buchholz CJ, Müller UC (2009) Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. J Immunol 182(12):7613–7624. doi:10.4049/jimmunol.0803366 PubMedCrossRef

Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ (2012) Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32(39):13454–13469. doi:10.1523/JNEUROSCI.1292-12.2012 PubMedCentralPubMedCrossRef

Bajetto A, Bonavia R, Barbero S, Piccioli P, Costa A, Florio T, Schettini G (1999) Glial and neuronal cells express functional chemokine receptor CXCR4 and its natural ligand stromal cell-derived factor 1. J Neurochem 73(6):2348–2357PubMedCrossRef

Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617):640–644. doi:10.1038/385640a0 PubMedCrossRef

10.

Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM (2006) Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9(7):917–924. doi:10.1038/nn1715 PubMedCrossRef

11.

Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR (2012) A progressive mouse model of Parkinson’s disease: the Thy1-aSyn (“Line 61”) mice. Neurotherapeutics: J Am Soc Exp Neurotherap 9(2):297–314. doi:10.1007/s13311-012-0104-2 CrossRef

12.

Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97(2):571–576PubMedCentralPubMedCrossRef

13.

Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A, Meucci O (2010) Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons. J Biol Chem 285(14):10563–10571. doi:10.1074/jbc.M109.035477 PubMedCentralPubMedCrossRef

14.

Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 5(2):e9313. doi:10.1371/journal.pone.0009313 PubMedCentralPubMedCrossRef

15.

Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27(34):9220–9232. doi:10.1523/JNEUROSCI.2617-07.2007 PubMedCrossRef

16.

de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73(4):685–697. doi:10.1016/j.neuron.2011.11.033 PubMedCentralPubMedCrossRef

17.

Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 106(31):13010–13015. doi:10.1073/pnas.0903691106 PubMedCentralPubMedCrossRef

18.

Eizenberg O, Faber-Elman A, Lotan M, Schwartz M (1995) Interleukin-2 transcripts in human and rodent brains: possible expression by astrocytes. J Neurochem 64(5):1928–1936PubMedCrossRef

19.

Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24(42):9434–9440. doi:10.1523/JNEUROSCI.3080-04.2004 PubMedCrossRef

20.

Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4:47. doi:10.1186/1750-1326-4-47 PubMedCentralPubMedCrossRef

21.

Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, Nuber S, Masliah E (2013) Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein. Am J Pathol 182(3):940–953. doi:10.1016/j.ajpath.2012.11.018 PubMedCentralPubMedCrossRef

22.

Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O (2012) alpha-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis 47(2):258–267. doi:10.1016/j.nbd.2012.04.009 PubMedCentralPubMedCrossRef

23.

Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 95(18):10896–10901PubMedCentralPubMedCrossRef

24.

Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10(4):717–721PubMedCrossRef

25.

Hashimoto M, Masliah E (1999) Alpha-synuclein in Lewy body disease and Alzheimer’s disease. Brain Pathol 9(4):707–720PubMedCrossRef

26.

Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH (2002) Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37(4):314–327PubMedCrossRef

27.

Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T (1995) The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14(2):467–475PubMedCrossRef

28.

Iwatsubo T, Yamaguchi H, Fujimuro M, Yokosawa H, Ihara Y, Trojanowski JQ, Lee VM (1996) Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol 148(5):1517–1529PubMedCentralPubMed

29.

Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287(23):19440–19451. doi:10.1074/jbc.M112.346072 PubMedCentralPubMedCrossRef

30.

Kohler G, Milstein C (1976) Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6(7):511–519. doi:10.1002/eji.1830060713 PubMedCrossRef

31.

Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27(6):1405–1410. doi:10.1523/JNEUROSCI.4564-06.2007 PubMedCrossRef

32.

Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19(8):312–318PubMedCrossRef

33.

Lalonde R, Qian S (2007) Exploratory activity, motor coordination, and spatial learning in Mchr1 knockout mice. Behav Brain Res 178(2):293–304. doi:10.1016/j.bbr.2007.01.006 PubMedCrossRef

34.

Lalonde R, Strazielle C (2009) Exploratory activity and motor coordination in old versus middle-aged C57BL/6J mice. Arch Gerontol Geriatr 49(1):39–42. doi:10.1016/j.archger.2008.04.009 PubMedCrossRef

35.

Lansbury PT Jr (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci USA 96(7):3342–3344PubMedCentralPubMedCrossRef

36.

Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14(1):38–48. doi:10.1038/nrn3406 PubMedCrossRef

37.

Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT (2002) Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322(5):1089–1102PubMedCrossRef

38.

Lee HJ, Suk JE, Bae EJ, Lee SJ (2008) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun 372(3):423–428. doi:10.1016/j.bbrc.2008.05.045 PubMedCrossRef

39.

Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285(12):9262–9272. doi:10.1074/jbc.M109.081125 PubMedCentralPubMedCrossRef

40.

Lee SJ, Lim HS, Masliah E, Lee HJ (2011) Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res 70(4):339–348. doi:10.1016/j.neures.2011.05.008 PubMedCentralPubMedCrossRef

41.

Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K (2012) Trans-synaptic spread of tau pathology in vivo. PLoS One 7(2):e31302. doi:10.1371/journal.pone.0031302 PubMedCentralPubMedCrossRef

42.

Luthi-Carter R (2003) Progress towards a vaccine for Huntington’s disease. Mol Ther 7(5 Pt 1):569–570PubMedCrossRef

43.

Mandler M, Rockenstein E, Ubhi K, Hansen L, Adame A, Michael S, Galasko D, Santic R, Mattner F, Masliah E (2012) Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer’s disease and in AβPP transgenic mice using a novel monoclonal antibody. J Alzheimers Dis 28(4):783–794. doi:10.3233/JAD-2011-111208 PubMed

44.

Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 46(6):857–868. doi:10.1016/j.neuron.2005.05.010 PubMedCrossRef

45.

Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6(4):e19338. doi:10.1371/journal.pone.0019338 PubMedCentralPubMedCrossRef

46.

Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287(5456):1265–1269PubMedCrossRef

47.

Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) beta-Amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci USA 98(21):12245–12250. doi:10.1073/pnas.211412398 PubMedCentralPubMedCrossRef

48.

McKeith IG (2000) Spectrum of Parkinson’s disease, Parkinson’s dementia, and Lewy body dementia. Neurol Clin 18(4):865–902PubMedCrossRef

49.

Menéndez-González M, Pérez-Piñera P, Martínez-Rivera M, Muñiz AL, Vega JA (2011) Immunotherapy for Alzheimer’s disease: rational basis in ongoing clinical trials. Curr Pharm Des 17(5):508–520PubMedCrossRef

50.

Metz GA, Schwab ME (2004) Behavioral characterization in a comprehensive mouse test battery reveals motor and sensory impairments in growth-associated protein-43 null mutant mice. Neuroscience 129(3):563–574. doi:10.1016/j.neuroscience.2004.07.053 PubMedCrossRef

51.

Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A (2003) DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Ther 7(5 Pt 1):572–579PubMedCrossRef

52.

Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408(6815):982–985. doi:10.1038/35050116 PubMedCrossRef

53.

Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20(9):3214–3220PubMed

54.

Nishiyori A, Minami M, Ohtani Y, Takami S, Yamamoto J, Kawaguchi N, Kume T, Akaike A, Satoh M (1998) Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett 429(2):167–172PubMedCrossRef

55.

Okuno T, Nakatsuji Y, Kumanogoh A, Moriya M, Ichinose H, Sumi H, Fujimura H, Kikutani H, Sakoda S (2005) Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson’s disease. J Neurosci Res 81(6):874–882. doi:10.1002/jnr.20599 PubMedCrossRef

56.

Olanow CW, Prusiner SB (2009) Is Parkinson’s disease a prion disorder? Proc Natl Acad Sci USA 106(31):12571–12572. doi:10.1073/pnas.0906759106 PubMedCentralPubMedCrossRef

57.

Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D (1997) Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 387(6633):611–617. doi:10.1038/42491 PubMedCrossRef

58.

Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL (2007) Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem 282(8):5862–5870. doi:10.1074/jbc.M608126200 PubMedCrossRef

59.

Ransohoff RM (2009) Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 31(5):711–721. doi:10.1016/j.immuni.2009.09.010 PubMedCentralPubMedCrossRef

60.

Rockenstein E, Crews L, Masliah E (2007) Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59(11):1093–1102. doi:10.1016/j.addr.2007.08.013 PubMedCrossRef

61.

Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68(5):568–578. doi:10.1002/jnr.10231 PubMedCrossRef

62.

Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA (2013) Incidence and pathology of synucleinopathies and tauopathies related to Parkinsonism. JAMA Neurol :1–7. doi:10.1001/jamaneurol.2013.114

63.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173–177. doi:10.1038/22124 PubMedCrossRef

64.

Schneeberger A, Mandler M, Mattner F, Schmidt W (2010) AFFITOME^® technology in neurodegenerative diseases: the doubling advantage. Hum Vaccin 6(11):948–952PubMedCrossRef

65.

Schneeberger A, Mandler M, Mattner F, Schmidt W (2012) Vaccination for Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S11–S13. doi:10.1016/S1353-8020(11)70006-2 PubMedCrossRef

66.

Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S (2010) A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 30(24):8083–8095. doi:10.1523/JNEUROSCI.1091-10.2010 PubMedCentralPubMedCrossRef

67.

Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, Wisniewski T (2002) Immunization delays the onset of prion disease in mice. Am J Pathol 161(1):13–17. doi:10.1016/S0002-9440(10)64151-X PubMedCentralPubMedCrossRef

68.

Singh VK, Mehrotra S, Agarwal SS (1999) The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 20(2):147–161PubMedCrossRef

69.

Solomon B (2007) Active immunization against Alzheimer’s beta-amyloid peptide using phage display technology. Vaccine 25(16):3053–3056. doi:10.1016/j.vaccine.2007.01.069 PubMedCrossRef

70.

Sonobe Y, Yawata I, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A (2005) Production of IL-27 and other IL-12 family cytokines by microglia and their subpopulations. Brain Res 1040(1–2):202–207. doi:10.1016/j.brainres.2005.01.100 PubMedCrossRef

71.

Spencer B, Michael S, Shen J, Kosberg K, Rockenstein E, Patrick C, Adame A, Masliah E (2012) Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD. Mol Therapy: J Am Soc Gene Therapy. doi:10.1038/mt.2012.66

72.

Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T, Masliah E (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson’s and Lewy body diseases. J Neurosci 29(43):13578–13588. doi:10.1523/JNEUROSCI.4390-09.2009 PubMedCentralPubMedCrossRef

73.

Streit WJ, Mrak RE, Griffin WS (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflamm 1(1):14. doi:10.1186/1742-2094-1-14 CrossRef

74.

Trojanowski JQ, Lee VM (1998) Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 55(2):151–152PubMedCrossRef

75.

Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9(4):397–405PubMedCentralPubMedCrossRef

76.

Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J 274(7):1862–1877. doi:10.1111/j.1742-4658.2007.05733.x PubMedCrossRef

77.

Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, Rockenstein E, May V, Winkler J, Masliah E (2012) Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy. Exp Neurol 234(2):405–416. doi:10.1016/j.expneurol.2012.01.008 PubMedCentralPubMedCrossRef

78.

Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, Whitney K, Masliah E (2010) Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 30(18):6236–6246. doi:10.1523/JNEUROSCI.0567-10.2010 PubMedCentralPubMedCrossRef

79.

Valera E, Masliah E (2013) Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther. doi:10.1016/j.pharmthera.2013.01.013 PubMed

80.

van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G (2000) Neuropathology in mice expressing human alpha-synuclein. J Neurosci 20(16):6021–6029PubMed

81.

Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr (1996) NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35(43):13709–13715. doi:10.1021/bi961799n PubMedCrossRef

82.

Wilcock DM, Colton CA (2008) Anti-amyloid-beta immunotherapy in Alzheimer’s disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15(4):555–569PubMedCentralPubMed

83.

Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 108(10):4194–4199. doi:10.1073/pnas.1100976108 PubMedCentralPubMedCrossRef

Title: Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials
Authors: Markus Mandler
Elvira Valera
Edward Rockenstein
Harald Weninger
Christina Patrick
Anthony Adame
Radmila Santic
Stefanie Meindl
Benjamin Vigl
Oskar Smrzka
Achim Schneeberger
Frank Mattner
Eliezer Masliah
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 6/2014
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-014-1256-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes

Mutually exclusive mutations of KIT and RAS are associated with KIT mRNA expression and chromosomal instability in primary intracranial pure germinomas

BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease

ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology

Subgroup-specific localization of human medulloblastoma based on pre-operative MRI